← Browse by Condition
Medical Condition

lymphoma large b cell diffuse

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT06890884 Phase 2
Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Enrollment
594 pts
Location
United States, Belgi...
Sponsor
Merck Sharp & Dohme LLC
View Trial →